Erasca Announces $150 Million Public Offering; Shares Drop 8% After Market Open

Erasca Inc. (ERAS) announced a $150 million public offering of common stock on January 21, 2026, to fund ongoing clinical trials and operational expansion. The company plans to use proceeds for research and development in oncology therapeutics, with no immediate dilution expected beyond the offering. The announcement triggered a sharp 8% decline in ERAS shares during pre-market trading, closing at $14.20 on January 21, 2026, after rising 3.5% earlier in the session. Analysts cited investor concern over potential share dilution and the timing of capital raising amid recent pipeline setbacks. Erasca’s Phase 2 trial data for its lead compound, ERS-101, is due by Q3 2026, which could influence future funding needs.